On June 26, Twist Bioscience rose 5.41% in regular trading, trading at $101.81/share, with turnover of $60.94 million. The stock continued its accelerating upward trajectory after breaking through Canaccord Genuity's previously assigned $90 price target.

On the news front, the rally represents an extension of strong momentum following multiple analyst upgrades. Canaccord Genuity initiated coverage with a Buy rating and $90 price target, significantly above the market consensus target of $73.12. Earlier, Leerink Partners upgraded the stock to Outperform from Market Perform, raising its target to $70 from $55 following Q2 results that beat sales guidance. The company guided fiscal Q3 revenue of $114M-$115M versus the FactSet estimate of $111.3M, and raised full-year sales guidance to $435M-$440M. Management also projected adjusted EBITDA breakeven by fiscal Q4. Dilution concerns from a $200 million shelf registration filed on June 19 initially caused a pullback, but market sentiment quickly recovered as bullish analyst coverage provided strong support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)